STOCK TITAN

Galapagos Nv SEC Filings

GLPG Nasdaq

Welcome to our dedicated page for Galapagos Nv SEC filings (Ticker: GLPG), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.

In biotech, a single footnote can conceal years of lab work. Galapagos NV’s filings detail complex phase-2 oncology reads, milestone payments from AbbVie-era alliances, and the cost of its decentralized cell therapy platform. Investors track pipeline timelines and cash runway in minute detail, yet the raw documents are dense. Stock Titan turns that hassle into clarity—Galapagos NV SEC filings explained simply so you can focus on decisions, not deciphering.

Need the latest Galapagos NV quarterly earnings report 10-Q filing or curious how cash burn shifted after a new trial launch? Our AI-powered summaries spotlight R&D spend, patient enrollment metrics, and collaboration revenue in seconds. Real-time alerts push Galapagos NV Form 4 insider transactions real-time to your dashboard, while side-by-side charts offer Galapagos NV earnings report filing analysis without scrolling through exhibits. Compare segment spending quarter over quarter without opening a PDF.

From Galapagos NV insider trading Form 4 transactions and executive stock moves to an Galapagos NV 8-K material events explained after an FDA update, every document arrives the moment EDGAR posts it. You’ll also find the Galapagos NV annual report 10-K simplified, the Galapagos NV executive stock transactions Form 4 log, and a plain-English look at the Galapagos NV proxy statement executive compensation tables. Want help understanding Galapagos NV SEC documents with AI? It’s built in—complete coverage, instant context, smarter biotech investing.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
current report
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
current report
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
current report
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
current report
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
current report
-
Rhea-AI Summary

Galapagos NV (GLPG) furnished a Form 6‑K as a foreign private issuer. The report attaches a press release dated October 23, 2025 as Exhibit 99.1 and incorporates it by reference into the company’s Registration Statements on Form S‑8.

The company indicates it files annual reports under cover of Form 20‑F. The Form 6‑K was signed by Company Secretary Annelies Denecker on October 24, 2025.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
current report
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
current report
-
Rhea-AI Summary

Galapagos NV furnished a Form 6-K and attached a press release dated October 16, 2025 as Exhibit 99.1.

The company states that the information in this report, including Exhibit 99.1, except for quotes by Henry Gosebruch and Fred Blakeslee, is incorporated by reference into its Registration Statements on Form S-8. Galapagos files annual reports on Form 20-F.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
current report
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
current report
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
current report

FAQ

What is the current stock price of Galapagos Nv (GLPG)?

The current stock price of Galapagos Nv (GLPG) is $34.12 as of January 14, 2026.

What is the market cap of Galapagos Nv (GLPG)?

The market cap of Galapagos Nv (GLPG) is approximately 2.2B.
Galapagos Nv

Nasdaq:GLPG

GLPG Rankings

GLPG Stock Data

2.19B
49.19M
25.35%
22.9%
2.44%
Biotechnology
Healthcare
Link
Belgium
Mechelen